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under the receiver operating characteristic (ROC) curve was
calculated. In 6249 of 6405 (97.6%) pts. survival status was known
and in 5413 (86.6%) pts a complete data set was available. The same
methods were then applied in 2317 ta-TAVR pts with a complete data
set.
RESULTS In tv-TAVR 30dm was 5.7%. Based on multiple logistic
regression, 15 risk factors impacting mortality were identiﬁed
including age, COPD, bicuspide aortic valve and others. The area un-
der the ROC curve with a value of 0.69 afﬁrmed the quality of
discrimination of the established scoring model. The model was then
tested prospectively on 3920 pts with full data set treated in the year
2013. Slightly less 30dm was observed than predicted in the very high
risk pts reﬂecting medical progress 2013 versus 2011/2012. In ta-TAVR
30dm was 8.5%, 13 risks factors partly different from transvascular pts
were identiﬁed and then prospectively tested. Some misalignment
between observed and predicted mortality could be demonstrated,
reﬂecting signiﬁcant inﬂuence of the ta-TAVR procedure outside pts
inherited risks.
CONCLUSIONS Based on GARY data the above models allows the
prediction of TAVR operative risks. Risk factors between tv- and ta-
TAVR deviate and risk prediction should be evaluated separately.
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BACKGROUND Transcatheter aortic valve implantation (TAVI) is
mainly done via a conventional strategy (CS); i.e., under general
anesthesia (GA) in hybrid operating rooms with transesophageal Echo
(TEE) guidance. Some centers, mostly in Europe, have demonstrated
the feasibility of a minimally invasive strategy (MIS); i.e., under local
anesthesia and conscious sedation without TEE guidance. Nonethe-
less, the experience of MIS for TAVI is largely limited in the United
States. Herein, we describe the evolution of an academic, high volume
TAVI program using either self- or balloon-expandable valves and its
transition from a CS to a MIS.
METHODS We, retrospectively, studied all transfemoral TAVI cases
with both commercially available self-expandable and balloon
expandable valves done at our institution between March 2011 and
November 2014. Patients were dichotomized according to the strategy
(MIS and CS). In-hospital, 30-day outcomes, gross cost data, and
midterm survival were evaluated.
RESULTS One hundred and sixteen patients were included in the MIS
group and 91 patients were included in the CS group. Baseline char-
acteristics were similar between groups. Procedural success was
comparable (99.1 % in MIS and 98.9 % in CS, p¼1). One intraprocedural
death occurred in each group. Conversion rate to GA was low (3.4%).
Length of hospital stay was signiﬁcantly reduced in the MIS (median
3.0 days [2.0,5.0]) compared to CS group (median 6.0 days [3.5,8.0]).
Complication rates were low and comparable between groups. Thirty-
day mortality and 30-day stroke/ transient ischemic attack rates were
similar (4.3% vs 4.4%; p¼1 and 0.9% vs 1.1%; p¼0.45, respectively). At
median follow up of 230 days, no signiﬁcant difference in survival was
detected (89 % vs. 88 %, p¼0.9). MIS was associated with cost saving
compared to CS (16000 $/case).
CONCLUSIONS This is the largest comparison between a MIS and a CS
for TAVI performed in the United States. TAVI via MIS was associated
with a shorter postprocedural hospital stay, lower hospital costs, and
similar safety proﬁle while keeping procedural efﬁcacy as compared to
CS.
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BACKGROUND New-onset conduction delays are one of the most
frequent complications after transcatheter aortic valve implantation
(TAVI). The purpose of this study was to evaluate the incidence of
new-onset intraventricular delays after TAVI with Edwards Sapien
aortic valves implantation.
METHODS A total of 136 consecutive patients undergoing TAVI with
Edwards Sapien aortic valves were included into a single-center
perspective registry between August 2011 and April 2015; 106 patients
received Edwards Sapien valves and 30 patients received Edwards Sapien
3 valves. Intraventricular conduction delays – deﬁned as right or left
bundle branch block – were assessed on ECGs acquired before TAVI,
immediately after TAVI, 24 hours after TAVI, and before discharge.
RESULTS The incidence of new-onset intraventricular conduction
delays was higher in patients treated with the Edwards Sapien 3 valve
as compared to those treated with the Edward Sapien valve (46.6% vs.
18.8%, P¼0.004). However, in 46% of patients treated with the
Edward Sapien 3 valve intraventricular conduction delays were tran-
sient, with complete resolution at discharge. No difference was
observed between patients treated with the Edwards Sapien 3 valve
and those treated the Edward Sapien valve in terms of deﬁnitive
pacemaker implantation after TAVI (10.7% vs 14.2%, P¼0-76).
CONCLUSIONS TAVI with new-generation Edwards Sapien 3 valve
might be associated with an increased risk of new-onset intraventricular
conduction delays. The latter, however, appears to be transient and not to
correlate with an increased risk of deﬁnitive pacemaker implantation.
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BACKGROUND Previous studies have demonstrated that a high neutro-
phil to lymphocyte ratio (NLR) is amarker of inﬂammation andprogression
of atherosclerosis. NLR has also been shown to be signiﬁcantly elevated in
patientswith severe calciﬁc aortic stenosis.However, prognostic relevance
of highNLR in patients undergoingTranscatheter aortic valve replacement
(TAVR) on operative mortality is not clearly deﬁned.
METHODS We retrospectively evaluated 166 consecutive patients
undergoing TAVR at our institution between 2012 and 2014. Baseline
characteristics, 30 day major adverse cardiovascular events (MACE),
deﬁned as composite end point of stroke, myocardial infarction, car-
diovascular death or re-hospitalization, and 30 day all-cause mortality
were analyzed. NLR was calculated as ratio of absolute neutrophil
count to absolute lymphocyte count, prior to TAVR procedure.
RESULTS The mean ( SD) total white blood cell, absolute neutrophil
and lymphocyte counts were 6.8 ( 1.8) x 103/mL, 4.6 (1.6) x 103/mL and
1.2 (0.5) x 103/mL, respectively. The mean ( SD) NLR was 4.5 ( 2.5).
NLR was signiﬁcantly correlated with pulmonary artery systolic pressure
(r ¼ 0.23, p ¼ 0.008) and society of thoracic society (STS) score (r ¼ 0.21,
p ¼ 0.02). ). On multivariate cox regression survival analysis, after
adjusting for age, gender, ethnicity, STS score, left ventricular ejection
fraction, pulmonary artery systolic pressure, history of diabetes mellitus,
peripheral vascular and cerebrovascular disease, patients with a NLR > 4
had signiﬁcantly reduced survival at 30 days when compared to those
with NLR < 4 (83.6% vs. 95.6%, hazard ratio (HR) 4.23, 95% conﬁdence
interval (CI): 1.04 to 17.26, p ¼ 0.04).
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dergoing transcatheter aortic valve replacement, elevated neutrophil
to lymphocyte ratio was associated with increased mortality at 30
days. This effect was independent of previously established risk
predictors in these patients. More large scale randomized studies are
needed to further evaluate these results.
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BACKGROUND Transcatheter aortic valve-in-valve (ViV) implantation
inside failed bioprostheses is an alternative approach to repeat open
heart surgery for those with failed bioprosthetic valves. However,
stentless surgical valves lack ﬂuoroscopic markers and provide
distinctive challenges. Our objective was to compare clinical out-
comes following aortic ViV procedures in stentless vs. stented bio-
prostheses, using a large global registry.
METHODS A total of 1,104 aortic ViV procedures from the ViV Inter-
national Data (VIVID) registry were investigated (903 stented bio-
prostheses, 201 stentless).
RESULTS Patients with stentless bioprostheses were younger and had
similar STS risk of mortality scores when compared to their stentedcounterparts (74.7 12.4 vs. 78.68 8.3, p< 0.001; 9.8 8.4 vs. 10.5 9.3,
p¼0.41, respectively). Stentlessbioprostheseshada longermedian time to
failure and failed predominantly with regurgitation (12 vs. 9 years, p <
0.001; 57.6%vs. 25.6% regurgitation, p<0.001, respectively). The effective
oriﬁce area was larger in stentless valves than in stented ones (valve area
1.2  1.5 vs. 0.94  0.6 cm2, p ¼ 0.02, respectively), with smaller mean
gradients as well (27.1 vs. 37.63 mmHg, p < 0.001, respectively). Stentless
bioprostheses were more commonly treated with self-expandable devices
(66.8% vs. 54.5% of stented, p < 0.001) and transesophageal echocardi-
ography was more commonly utilized in these procedures (73.1% vs.
56.4%, p < 0.001). Device malposition was more common in stentless and
Mosaic surgical valves than in stentednon-Mosaicones (12.3%vs. 12.4%vs.
5.1%, p < 0.001, respectively). There was a greater need for second trans-
catheter heart valve device in stentless valves as well (8.5% vs. 3.6%, p ¼
0.002). Coronary obstruction was more common in stentless valves (5.8%
vs. 1%,p<0.001). Final aortic valve areawasgreater in stentlessprostheses
(1.75  0.4 vs. 1.41  0.6 cm2, p < 0.001) and post-procedure mean gradi-
entswere also lower in this group (11.7 7 vs. 17.2 9.6mmHg, p< 0.001).
There was a trend towards higher 30-day mortality in stentless valves
(8.4%vs. 5%, p¼ 0.07). However, 1-yearmortalitywas similar between the
groups (14% stentless vs. 16.6% stented, p ¼ 0.59).
CONCLUSIONS Aortic ViV procedures inside stentless bioprostheses
are challenging and associated with more device malposition, coro-
nary obstruction and a trend towards increased short-term mortality.
However, stentless ViV procedures offers improved hemodynamics
with similar survival rates at one year.
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BACKGROUND The latest generation of the balloon-expandable
Edwards SAPIEN device, the SAPIEN 3, has shown very positive re-
sults in recently published studies. Most notably, it demonstrated a
low rate in paravalvular regurgitation, a low rate in vascular access
site complications, a low stroke rate and a very low mortality rate.
These clinical outcomes are mainly due to signiﬁcant design im-
provements: downsizing of the delivery system (Edwards Commander
delivery system) with sizes of 14F (23 mm and 26 mm device) and 16F
(29mm device) and a paravalvular sealing cuff to reduce the amount
of residual paravalvular regurgitation. According to these changes,
new sizing recommendations were developed for the SAPIEN 3 device,
which even allows slight undersizing.
METHODS To analyze the percentage of patientswho couldhave received
a SAPIEN 3 device in a transfemoral TAVR patient cohort. We retrospec-
tively reviewed CT-scans of 201 TAVR patients implanted between
February 2014 (when the SAPIEN 3 was introduced at our hospital) and
April 2015 and compared the suitability for the SAPIEN 3 and SAPIEN XT
respectively, based on access vessel and/or the 3D annulus diameter.
RESULTS With respect to the new sizing guidelines for the SAPIEN 3,
196 patients (98%) of the 201 patients analyzed would have been suit-
able for an implantation with the new SAPIEN 3 device. In contrary, the
SAPIEN XT device could have been implanted in signiﬁcantly less pa-
tients (80%). The SAPIEN 3 device was ﬁnally implanted in 102 patients
(52%). The short-term outcome of this cohort showed excellent results.
Paravalvular regurgitation was virtually absent with the vast majority
having none or trace postinterventional aortic regurgitation on echo-
cardiography (90.7%). None of the patients had more than mild para-
valvular regurgitation. Major vascular access site complications or
major bleeding according to the VARC II criteria were not observed in
our cohort. Minor vascular complications and minor bleeding occurred
in 6.8 % and 3.9 % respectively. If vascular complication occurred, they
were related to closure device failure with subsequent stent graft im-
plantation. Thirty-day outcome showed a very low major stroke rate
(1.9%) and a low mortality rate (2.9%). However, we observed a 20.6%
permanent pacemaker rate in our SAPIEN 3 cohort.
